Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients

BACKGROUND: To date, standardized strategies for the treatment of recurrent glioma are lacking. Chemotherapy with the alkylating agent BCNU (1,3-bis (2-chloroethyl)-1-nitroso-urea) is a therapeutic option even though its efficacy and safety, particularly the risk of pulmonary fibrosis, remains contr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Jungk, Christine, Chatziaslanidou, Despina, Ahmadi, Rezvan, Capper, David, Bermejo, Justo Lorenzo, Exner, Janina, von Deimling, Andreas, Herold-Mende, Christel, Unterberg, Andreas
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4748520/
https://ncbi.nlm.nih.gov/pubmed/26865253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2131-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars